The U.S. just shipped two million doses of lenacapavir, a groundbreaking twice-a-year HIV-prevention injectable medication, ...

Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...

The United States said Tuesday it has delivered a new treatment to prevent HIV in two African countries, months after President Donald Trump dramatically cut global aid.

ORLANDO, Fla. — As the Trump administration works to slim down government spending, that includes millions of dollars in funding for HIV medications. LGBT+ Center Orlando was established in 1978. The ...

The Pennsylvania Department of Health will cut 25% of funding to the Part B of the Ryan White HIV/AIDS Program amid rising ...

(The Conversation is an independent and nonprofit source of news, analysis and commentary from academic experts.) Robin Lin Miller, Michigan State University (THE CONVERSATION) Protecting public ...

(THE CONVERSATION) Protecting public health abroad benefits Americans. In a globalized world, diseases and their social and economic impacts do not stay within national boundaries. Increased rates of ...

Gilead Sciences, Inc.’s GILD posted 3% year-over-year growth in total revenues for the third quarter of 2025. Total revenues comprise product sales and royalty, contract and other revenues. While ...

Some lawmakers and advocates are increasingly uncertain whether critical HIV and AIDS services will survive the federal government’s funding fight. The GOP’s House-passed budget bill seeks to cut over ...

In recent years, the story around HIV has shifted dramatically. What was once viewed as a life sentence is now increasingly seen as a manageable condition. Medication is responsible for much of that ...

HIV remains a major global health issue, affecting nearly 40 million people worldwide. Current treatments, known as antiretroviral therapy (ART), are highly effective at suppressing the virus and ...